MoonLake Immunotherapeutics (MLTX) Stock Forecast, Price Target & Predictions
MLTX Stock Forecast
MoonLake Immunotherapeutics stock forecast is as follows: an average price target of $100.00 (represents a 91.68% upside from MLTX’s last price of $52.17) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
MLTX Price Target
The average price target for MoonLake Immunotherapeutics (MLTX) is $100.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $100.00 to $100.00. This represents a potential 91.68% upside from MLTX's last price of $52.17.
MLTX Analyst Ratings
According to 7 Wall Street analysts, MoonLake Immunotherapeutics's rating consensus is 'Buy'. The analyst rating breakdown for MLTX stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
MoonLake Immunotherapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 01, 2024 | Raghuram Selvaraju | H.C. Wainwright | $100.00 | $43.97 | 127.43% | 91.68% |
| Apr 02, 2024 | Richard Law | Goldman Sachs | $62.00 | $48.60 | 27.57% | 18.84% |
| Aug 31, 2023 | Serge Belanger | Needham | $76.00 | $56.09 | 35.48% | 45.68% |
The latest MoonLake Immunotherapeutics stock forecast, released on Jul 01, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $100.00, which represents a 127.43% increase from the stock price at the time of the forecast ($43.97), and a 91.68% increase from MLTX last price ($52.17).
MoonLake Immunotherapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $81.00 |
| Last Closing Price | $52.17 | $52.17 | $52.17 |
| Upside/Downside | -100.00% | -100.00% | 55.26% |
In the current month, the average price target of MoonLake Immunotherapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to MoonLake Immunotherapeutics's last price of $52.17. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 15, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 12, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 26, 2024 | Wolfe Research | Peer Perform | Downgrade | |
| Jul 01, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 24, 2024 | Oppenheimer | Outperform | Initialise | |
| Apr 02, 2024 | Goldman Sachs | Neutral | Initialise | |
| Aug 31, 2023 | Needham | Buy | Initialise | |
| Feb 14, 2023 | Cantor Fitzgerald | Overweight | Initialise | |
| Nov 11, 2022 | Jefferies | Buy | Initialise | |
| Jul 22, 2022 | H.C. Wainwright | Buy | Initialise |
MoonLake Immunotherapeutics's last stock rating was published by H.C. Wainwright on Oct 15, 2024. The company gave MLTX a "Buy" rating, the same as its previous rate.
MoonLake Immunotherapeutics Financial Forecast
MoonLake Immunotherapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
MoonLake Immunotherapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. MLTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
MoonLake Immunotherapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict MLTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than MoonLake Immunotherapeutics's previous annual EBITDA (undefined) of $NaN.
MoonLake Immunotherapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-44.12M | $-44.97M | $-42.22M | $-39.47M | $-37.99M | $-27.39M | $-17.41M |
| High Forecast | $-44.12M | $-44.97M | $-42.22M | $-33.55M | $-27.14M | $-27.39M | $-17.41M |
| Low Forecast | $-44.12M | $-44.97M | $-42.22M | $-45.39M | $-45.83M | $-27.39M | $-17.41M |
| Surprise % | - | - | - | - | - | - | - |
MoonLake Immunotherapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MLTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
MoonLake Immunotherapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
MoonLake Immunotherapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to MLTX last annual SG&A of $NaN (undefined).
MoonLake Immunotherapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.70 | $-0.71 | $-0.67 | $-0.63 | $-0.60 | $-0.44 | $-0.28 |
| High Forecast | $-0.70 | $-0.71 | $-0.67 | $-0.53 | $-0.43 | $-0.44 | $-0.28 |
| Low Forecast | $-0.70 | $-0.71 | $-0.67 | $-0.72 | $-0.73 | $-0.44 | $-0.28 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, MoonLake Immunotherapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MLTX previous annual EPS of $NaN (undefined).
MoonLake Immunotherapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.37 | $33.86 | 1328.69% | Buy |
| AVTE | Aerovate Therapeutics | $2.56 | $13.00 | 407.81% | Hold |
| ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
| CMPX | Compass Therapeutics | $1.53 | $5.00 | 226.80% | Buy |
| GPCR | Structure Therapeutics | $31.48 | $99.00 | 214.49% | Buy |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| PLRX | Pliant Therapeutics | $14.37 | $35.50 | 147.04% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.28 | $8.25 | 92.76% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| MLTX | MoonLake Immunotherapeutics | $56.30 | $100.00 | 77.62% | Buy |
| AKRO | Akero Therapeutics | $30.61 | $50.00 | 63.35% | Buy |
| ELVN | Enliven Therapeutics | $24.39 | $39.50 | 61.95% | Buy |
| ETNB | 89bio | $7.98 | $12.00 | 50.38% | Buy |
| ACLX | Arcellx | $82.03 | $111.60 | 36.05% | Buy |
| NUVL | Nuvalent | $88.10 | $114.80 | 30.31% | Buy |
| TVTX | Travere Therapeutics | $17.14 | $21.75 | 26.90% | Buy |